gastroenteropancreatic neuroendocrine tumours
Oncology · 2015–2016
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanreotide Treatment of non-functional gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with unresectable locally advanced or metastatic disease that are… | Nov 2016 | Not recommended | 119 individuals Unicorn Foundation Australia · Unicorn Foundation |
| lanreotide Treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally advanced or metastatic disease. | Nov 2015 | Not recommended | 22 individuals Medical Oncology Group · Unicorn Foundation |
Who spoke
Unicorn Foundation · Medical Oncology Group · Unicorn Foundation Australia
What the PBS pays
$41M in government benefit over 2024–25, across 18,748 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lanreotide | $40.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.